Acticor Biotech: falls after capital increase
The biopharmaceutical company will use the proceeds of this capital increase to pursue its development plan in the emergency treatment of stroke, including the completion of the phase 2/3 ACTISAVE study.
On the basis of planned expenditure, net cash and financial debt at December 31, 2023, and the funds raised, Acticor estimates that it will be in a position to finance its operations until October 2024.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction